Revvity, Inc. (RVTY) is valued at $11.6 billion and offers health sciences solutions. Expected to report fiscal Q2 earnings on Jul. 28, analysts project a profit of $1.14 per share, a 6.6% decrease from last year. For fiscal 2025, analysts anticipate a profit of $4.82 per share.

RVTY shares have fallen 10.1% in the past year, underperforming the S&P 500 Index and Health Care Select Sector SPDR Fund. After Q1 earnings, revenue rose 2.3% to $664.8 million and adjusted EPS increased to $1.01. The company raised its fiscal 2025 revenue guidance.

Wall Street analysts give RVTY a “Moderate Buy” rating, with a mean price target of $118.69, suggesting a 20.5% potential upside. Analysts expect a rebound in EPS growth for fiscal 2026. This article is for informational purposes only and was originally published on Barchart.com.

Read more at Yahoo Finance: What to Expect From Revvity’s Report